СТУДЕНТАМ - копия / Вирусн.гепатиты / _методичка ВГВ
.pdfОценивается также эффективность профилактического лечения беременных с высокой вирусной нагрузкой нуклеозид(т)ными аналогами: ламивудином, телбувидином, тенофовиром .
Необходимо также дальнейшее обследование привитых, в особенности из групп риска, для оценки эффективности формирования иммунного ответа и последующей возможной коррекции тактики иммунизации в Национальном календаре.
Использованная литература:
1.Ko H.H., Wong D.K.H., Heathcote J. Management of Hepatitis B // Clin Gastroenterol Hepatol – 2011. – № 9(5). – P.385 – 391.
2.Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. // Am J Gastroenterol. – 2006. – № 101.
– Р. 1797–1803.
3.Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine vs lamivudine C.L.Lai, E.Gane, C.W.Hsu et al // Hepatology. – 2006.– V. 44.– P.229.
4.Галимова С.Ф., Маевская М.В., Ивашкин В.Т. Новый аналог нуклеозидов телбивудин в лечении хронического гепатита В // РФГГК. – 2007. – №5. – С. 55 – 59.
5.Review: Current Status of Antiviral Therapy for Hepatitis B // Ther Adv Gastroenterol. – 2008. - №1. – С.61–
6.Snow-Lampart A, Chappell BJ, Curtis M et al. Resistance surveillance for up to 144 weeks in HBeAg-positive and HBeAg-nagative hepatitis B patients treated with tenofovir DF showed no relationship between virologic breakthrough and emergence of genotypic changes in HBV polymerase // Hepatology2009;50 (Suppl.): 532A.
7.van Bömmel F, de Man RA, Wedemeyer H et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology2010; 51: 73–80.
8.Man-Fung Yuen, Ching-Lung Lai Treatment of chronic hepatitis B: Evolution over two decades // Journal of Gastroenterology and Hepatology. – 2011. – V.26. – Suppl. 1; 138–143.
9.Lai CL, Yuen MF. Chronic hepatitis B—new goals, new treatment // N. Engl. J. Med. 2008; 359:2488–91.
10.Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAgnegative chronic hepatitis B for up to 5 years. Gastroenterology2006;131: 1743–51.
11.Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudineresistant HBeAg-negative chronic hepatitis B. Hepatology2007; 45: 307–13.
12.Fung J, Lai CL, Yuen JC et al. Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population. Antivir. Ther. 2007; 12:41–6.
13.Lampertico P, Viganò M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology2005; 42: 1414–19.
14.Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year studyof 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133: 1445–51.
15.Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine StudyGroup. N. Engl. J. Med. 1998;339: 61–8.
16.Yuen MF, Seto WK, Chow DH et al. Long-term lamivudine therapy reduces the risk of long-term
complications of chronic hepatitis B infection even in patients without advanced disease. Antivir. Ther. 2007; 12: 1295– 303.
17.Yuen MF, Fung J, Wong DK, Lai CL. Prevention and management of drug resistance for antihepatitis B treatment. Lancet Infect. Dis. 2009; 9:256–64.
18.Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004; 351:1521–31.
19.Matsumoto A, Tanaka E, Rokuhara A et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol. Res. 2005; 32:173–84.
20.Eun JR, Jang BI, Kim TN, Lee HJ, Lee KS. The effect of lamivudine on preventing hepatocellular carcinoma in chronic hepatitis B: a retrospective studyof 2518 patients. Hepatology2006;44 (Suppl. 1): 550A.
21.Szmuness W. Hepatocellular carcinoma and the hepatitis B virus; evidence for a causal association. Prog Med Virol. 1978;24:40-69.
22.Han GR et al J.Hepatol 2011 Apr 15
23.Xu W-M et al J.Viral Hepatol 2009;16; 94-103.
24.Tenofovir and Entecavir are Most Effective Antiviral Agents for Chronic Hepatitis B; A Systematic Review and Bayesian Meta-Analyses; Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, Wong DK, Pham B, Ungar WJ, Einarson TR, Heathcote EJ, Krahn M // Gastroenterology (Jun 2010)
25.Telbivudine versus lamivudine in patients with chronic hepatitis B Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA; Globe Study Group // N Engl J Med. 2007 Dec 20;357(25):2576-88.
26.Pan C, Han GR, Zhai W, et al. A prospective open-label study to evaluate the efficacy, safety, and tolerability of telbivudine in HBeAg + chronic hepatitis B pregnant women. Program and Abstracts of The Liver Meeting 2010: American Association for the Study of Liver Diseases (AASLD) 61st Annual Meeting: Abstract 364.
27.Su GG, Pan KH, Zhao NF, Fang SH, Yang DH, Zhou Y. Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. World J Gastroenterol. 2004;10:910-912.
28.Xu WM, Cui YT, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat. 2009;16:94-103.
29.Shi Z, Yang Y, Ma L, Li X, Schreiber A. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis // Obstet Gynecol. 2010 Jul;116(1):147-59.
30.Buchanan C, Tran TT. Management of chronic hepatitis B in pregnancy. Clin Liver Dis. 2010;14:495-504.
31.Вирусные гепатиты и холестатические заболевания / Юджин Р.Щифф, Майкл Ф.Соррел, Уиллис С.Мэддрей; пер.с англ. – М.: ГЭОТАР-Медиа, 2010. – 408 с.
32.Lok AS, McMahon BJ. AASLD Practice guidelines: chronic hepatitis B // Hepatology. – 2007. – №45. – Р.507-539.
33.Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45:529–538.
34.Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiencyvirus: the D:A:D study. Arch Intern Med 2006; 166:1632–1641.
35.Chien-Jen Chen; Hwai-I Yang Natural History of Chronic Hepatitis B REVEALed // J Gastroenterol Hepatol. 2011;26(4):628-638.
36.Lavanchy D. J. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures // Viral Hepat. – 2004. – Mar;11(2). – Р. 97-107.
37.Recommendations for Identification and Public Health Management of Persons With Chronic Hepatitis B Virus Infection CindyM. Weinbaum, Ian Williams, Eric E. Mast et all //
38.World Health Organization. Hepatitis B. Geneva, Switzerland: World Health Organization; 2000. Available at http://www.who.int/mediacentre/factsheets/fs204/en.
39.Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005;34:1329-39.
40.CDC. Surveillance for acute viral hepatitis--United States, 2006. In: CDC Surveillance Summaries, March 21,
2008. MMWR 2008;57(No. SS-2).
41.Care of Patients With Chronic Hepatitis B and HIV Co-Infection: Recommendations From an HIV-HBV International Panel Vincent Soriano, Massimo Puoti, Maurizio Bonacini et al // AIDS. 2005; 19 (3): 221-240.
42.Brian J. McMahon Natural History of Chronic Hepatitis B -- Clinical Implications // Medscape J Med. 2008;10(4):91
43.McMahon BJ. Epidemiology and natural historyof hepatitis B. Semin Liver Dis. 2005;25 Suppl 1:3-8.
44.Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007;45:1056-1075.
45.Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2001;34:617-
46.McMahon BJ, Holck P, Bulkow L, Snowball MM. Serologic and clinical outcomes 1536 Alaska Natives
chronically infected with hepatitis B virus. Ann Intern Med. 2001:135;759-768.
47.Lok AS, Lai CL, Wu PC, Leung EK, Lam TS. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology. 1987;92:1839-1843.
48.Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991;100:182-188.
49.Norder H, Courouce AM, Coursaget P, et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology. 2004;47:289-309.
50.Sakamoto T TY, Simonetti J, Osiowy C, et al. Classification of hepatitis B virus genotype B into two major forms based on characterization of a novel subgenotype in the Arctic indigenous populations. J Infect Dis. 2007;196:1487-1492.
51.Chan HL, Hui AY, Wong ML, et al. Genotype C hepatitis B virus infection is associated with an increased risk ofhepatocellular carcinoma. Gut. 2004;53:1494-1498.
52.Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology. 2002;122:1756-1762.
53.Fung SK, Lok AS. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology. 2004;40:790-792.
54.Livingston SE, Simonetti JP, McMahon BJ, et al. Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: Preponderance of genotype F. J Infect Dis. 2007;195:5-11.
55.Chu CJ, Keeffe EB, Han SH, Pet al. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology. 2003;125:444-451.
56.Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer. 1998;75:347-354.
57.Hadziyannis SJ. Hepatitis D. Clin Liver Dis. 1999;3:309-325.
58.Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1212.
59.Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology. 2006;43:S173-S181.
60.Hui CK, Leung N, Yuen ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology. 2007;46:395-401.
61.Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastro Hepatol. 2007;5:890–897.
62.Ильянкова А.А., Крель П.Е. Клинико-морфологическая характеристика внепеченочных проявлений HBV-инфекции // Росс.журнал гастроэнтерологии, гепатологии, колопроктологии.-2001.-№3.-С.11-18.
63.Косминкова Е.Н., Козловская Л.В. Особенности поражения почек при хронических диффузных заболеваниях печени, обусловленных вирусом гепатита В // Тер.архив.-1992.-Т.64, №6.-С.43-46.
64.De Jongh FE, Janssen HL, De Man RA, et al. Survival and prognostic indicators in hepatitis B surface antigenpositive cirrhosis of the liver. Gastroenterology1992;103:1630-1635
65.Fattovich G, Brollo L, Giustina G, et al. Natural history and prognostic factors for chronic hepatitis B. Gut 1991;32:294298
66.McMahon B.J., Bulkow L., Harpster A., Snowball M., Lanier A., Sacco F., Dunaway E., et al. Screening for hepatocellular carcinoma in Alaska Natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology2000;32:842-6.
67.Sherman M., Peltekian K.M., Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995;22:432-7.
68.Yuen M.F., Cheng C.C., Lauder I.J., Lam S.K., Ooi C.G.C., Lai C.L. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology2000;31:330-5.
69.Bosch, F. X., Ribes, J., Diaz, M. & Cleries, R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127 (Suppl. 1), S5-S16 (2004).
70.Parkin, D. M. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 118, 3030-3044 (2006). 70
71.Beasley, R. P Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 61, 1942-1956 (1988).
72.Chen, J. D. et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liverrelated death. Gastroenterology138, 1747-1754 (2010). 72
73.Yuen, M. F. et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J. Hepatol. 50, 80-88 (2009).
74.Yang, H. I. et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J. Clin. Oncol. 28, 2437-2444 (2010).
75.Liu, S. et al. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a metaanalysis. J. Natl Cancer Inst. 101,1066-1082 (2009).
76.Yang, H. I. et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular
carcinoma. J. Natl Cancer Inst. 100,1134-1143 (2008).
77.Kao, J. H. Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol. Int. 1, 415-430
(2007).
78.Chen, C. J. et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295, 65-73 (2006).
79.Yang, H. I. et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N. Engl. J. Med. 347, 168-174
(2002).
80.Frodsham, A. J. et al. Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence. Proc. Natl Acad. Sci. USA 103, 9148-9153 (2006).
81.Chang, M. H. et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year followup study. J. Natl Cancer Inst. 101,1348-1355 (2009).
82.Ju Dong Yang, Lewis R. Roberts Hepatocellular Carcinoma: A Global View // Nat Rev Gastroenterol Hepatol. - 2010;7(7)
83.Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 1995;20:992-1000.
84.Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology2001;34: 1225-41.
85.Seage GR III, Mayer KH, Lenderking WR, et al. HIV and hepatitis B infection and risk behavior in young gay and bisexual men. Public Health Rep 1997;112:158-67.
86.MacKellar DA, Valleroy LA, Secura GM, et al. Two decades after vaccine license: hepatitis B immunization and infection among young men who have sex with men. Am J Public Health 2001;91:965-71.
87.Weinbaum CM, Lyerla R, MacKellar DA, et al. The Young Men's Survey Phase II: hepatitis B immunization and infection among young men who have sex with men. Am J Public Health 2008;98:839-45.
88.Schreeder MT, Thompson SE, Hadler SC, et al. Hepatitis B in homosexual men: prevalence of infection and factors related to transmission. J Infect Dis 1982;146:7-15.
89.Breastfeeding of Newborns by Mothers Carrying Hepatitis B Virus: A Meta-analysis and Systematic Review. Shi Z, Yang Y, Wang H et all //Arch Pediatr Adolesc Med. 2011 Sep;165(9):837-46.
90.Знайко О.О. Место нуктеоз(т)идных аналогов в лечении хронического гепатита В // Гепатологический форум. – 2010. - №1. – С.11.-21.
91.Бакулин И.Г., Сандлер Ю.Г. Препараты интерферонового ряда при хроническом гепатите В // Гепатологический форум. – 2010. - №1. – С. 5.-10.
92.Протокол диагностики и лечения больных вирусными гепатитами В и С Н.Д.Ющук, Е.А.Климова, О.О.Знайко и др. // РЖГГК. – 2010. - №6.– С. 4 – 60.
октаплекс
рифаксимин взрослым и детям старше 12 лет: по 600 мг каждые8 ч или 1200 мг каждые 8–12 ч.